Overview

Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Status:
Completed
Trial end date:
2021-01-07
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.
Phase:
Phase 3
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Collaborator:
GlaxoSmithKline